Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > RVV Clinical-Trial phase 3 >>> Important dates >>>

<< Previous

Bullboard Posts

Next >>

Post by TheTerminator1on Jul 15, 2021 7:55am

148 Views

Post# 33548032

RVV Clinical-Trial phase 3 >>> Important dates >>>

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	1000 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Double-blind, placebo controlled
Primary Purpose:	Treatment
Official Title:	Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Actual Study Start Date :	November 27, 2020
Estimated Primary Completion Date :	July 25, 2021
Estimated Study Completion Date :	August 25, 2021